Open AccessEffect of Trastuzumab among HER2-Positive Breast Cancer Patients that Achieved Pathologic Complete Response after Neoadjuvant Chemotherapy
Author(s) -
Xinguang Wang,
Yingjian He,
Zhaoqing Fan,
Tianfeng Wang,
Yuntao Xie,
Jinfeng Li,
Tao Ouyang
Publication year - 2019
Publication title -
breast care
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.767
H-Index - 30
eISSN - 1661-3805
pISSN - 1661-3791
DOI - 10.1159/000495186
Subject(s) - trastuzumab , medicine , breast cancer , oncology , hazard ratio , chemotherapy , multivariate analysis , proportional hazards model , cancer , confidence interval
We sought to investigate the incremental benefit of trastuzumab in patients with HER2-positive breast cancer who achieved a pathologic complete response (pCR) after neoadjuvant chemotherapy (NACT).
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom